LIQUIDIA CORPORATION Retained Earnings
LIQUIDIA CORPORATION (LQDA) had Retained Earnings of -$498.73 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-12
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$498.73M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$573.45M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$626.31M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$640.87M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$498.73M 10-Q · filed 2026-08-12 | |
| 2026-03-31 | -$573.45M 10-Q · filed 2026-05-11 | |
| 2025-12-31 | -$626.31M 10-Q · filed 2026-08-12 | |
| 2025-09-30 | -$640.87M 10-Q · filed 2025-11-03 | |
| 2025-06-30 | -$637.34M 10-Q · filed 2025-08-12 | |
| 2025-03-31 | -$595.76M 10-Q · filed 2025-05-08 | |
| 2024-12-31 | -$557.39M 10-K · filed 2026-03-05 | -$559.49M 10-K · filed 2025-03-19 |
| 2024-09-30 | -$518.88M 8-K · filed 2025-05-08 | -$521.12M 10-Q · filed 2024-11-13 |
| 2024-06-30 | -$487.85M 8-K · filed 2025-05-08 | -$497.97M 10-Q · filed 2024-08-07 |
| 2024-03-31 | -$459.18M 8-K · filed 2025-05-08 | -$470.03M 10-Q · filed 2024-05-13 |
| 2023-12-31 | -$429.10M 8-K · filed 2025-05-08 | |
| 2023-09-30 | -$401.65M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | -$385.86M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | -$362.34M 10-Q · filed 2023-05-08 | |
| 2022-12-31 | -$350.60M 10-K · filed 2024-03-13 | |
| 2022-09-30 | -$344.06M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | -$334.97M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | -$325.52M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | -$309.58M 10-K · filed 2023-03-20 | -$309.58M 10-K · filed 2022-03-17 |
| 2021-09-30 | -$298.02M 10-Q · filed 2021-11-03 | |
| 2021-06-30 | -$290.74M 10-Q · filed 2021-08-10 | |
| 2021-03-31 | -$284.19M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | -$275.00M 10-K · filed 2022-03-17 | |
| 2019-12-31 | -$215.24M 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |